| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 335 | 2023 | 2341 | 24.950 |
Why?
|
| Carcinoma, Transitional Cell | 121 | 2023 | 962 | 10.870 |
Why?
|
| Cystectomy | 116 | 2023 | 623 | 9.550 |
Why?
|
| BCG Vaccine | 44 | 2023 | 399 | 5.260 |
Why?
|
| Genetic Therapy | 21 | 2023 | 1616 | 3.580 |
Why?
|
| Neoplasm Invasiveness | 84 | 2023 | 3981 | 2.860 |
Why?
|
| Adjuvants, Immunologic | 26 | 2023 | 657 | 2.550 |
Why?
|
| Interferon-alpha | 14 | 2023 | 889 | 2.470 |
Why?
|
| Administration, Intravesical | 34 | 2023 | 162 | 2.370 |
Why?
|
| Ureteral Neoplasms | 18 | 2022 | 228 | 2.120 |
Why?
|
| Neoplasm Recurrence, Local | 68 | 2023 | 10035 | 1.890 |
Why?
|
| Neovascularization, Pathologic | 23 | 2008 | 1547 | 1.740 |
Why?
|
| Urothelium | 21 | 2020 | 254 | 1.740 |
Why?
|
| ErbB Receptors | 23 | 2012 | 2295 | 1.690 |
Why?
|
| Carcinoma in Situ | 12 | 2020 | 487 | 1.630 |
Why?
|
| Adenoviridae | 15 | 2020 | 1459 | 1.620 |
Why?
|
| Gene Expression Regulation, Neoplastic | 35 | 2021 | 8873 | 1.450 |
Why?
|
| Neoadjuvant Therapy | 37 | 2023 | 4975 | 1.420 |
Why?
|
| Humans | 400 | 2023 | 261506 | 1.360 |
Why?
|
| Antineoplastic Agents | 32 | 2023 | 14289 | 1.340 |
Why?
|
| Muscle Neoplasms | 7 | 2017 | 109 | 1.320 |
Why?
|
| Genetic Vectors | 13 | 2020 | 1694 | 1.300 |
Why?
|
| Kidney Neoplasms | 30 | 2021 | 3022 | 1.300 |
Why?
|
| Urinary Bladder | 25 | 2023 | 575 | 1.270 |
Why?
|
| Biomarkers, Tumor | 39 | 2021 | 10331 | 1.230 |
Why?
|
| Male | 261 | 2021 | 123000 | 1.160 |
Why?
|
| Neoplasm Staging | 80 | 2023 | 13658 | 1.140 |
Why?
|
| Aged | 186 | 2021 | 70117 | 1.140 |
Why?
|
| Interleukin-8 | 18 | 2007 | 519 | 1.070 |
Why?
|
| Middle Aged | 189 | 2021 | 86204 | 1.030 |
Why?
|
| Disaccharides | 6 | 2017 | 31 | 1.020 |
Why?
|
| Cholic Acids | 6 | 2017 | 30 | 1.020 |
Why?
|
| Neoplasm Transplantation | 20 | 2017 | 1519 | 0.980 |
Why?
|
| Cisplatin | 23 | 2023 | 2432 | 0.960 |
Why?
|
| In Situ Hybridization, Fluorescence | 10 | 2019 | 2232 | 0.950 |
Why?
|
| Chemotherapy, Adjuvant | 33 | 2021 | 3890 | 0.910 |
Why?
|
| Female | 218 | 2021 | 141928 | 0.900 |
Why?
|
| Urology | 6 | 2023 | 128 | 0.880 |
Why?
|
| Vascular Endothelial Growth Factor A | 19 | 2008 | 1533 | 0.870 |
Why?
|
| Lymph Node Excision | 23 | 2021 | 1959 | 0.870 |
Why?
|
| Mice, Nude | 38 | 2020 | 4307 | 0.860 |
Why?
|
| Urologic Neoplasms | 6 | 2018 | 188 | 0.850 |
Why?
|
| Carcinoma | 14 | 2020 | 2578 | 0.850 |
Why?
|
| Disease Progression | 32 | 2021 | 6682 | 0.850 |
Why?
|
| Aged, 80 and over | 83 | 2021 | 29902 | 0.810 |
Why?
|
| Matrix Metalloproteinase 9 | 13 | 2012 | 360 | 0.800 |
Why?
|
| Fibroblast Growth Factor 2 | 15 | 2006 | 223 | 0.790 |
Why?
|
| Drug Resistance, Neoplasm | 14 | 2020 | 5178 | 0.790 |
Why?
|
| Carcinoma, Renal Cell | 18 | 2015 | 2326 | 0.750 |
Why?
|
| Prognosis | 62 | 2023 | 21713 | 0.750 |
Why?
|
| Treatment Outcome | 68 | 2023 | 32848 | 0.740 |
Why?
|
| Clinical Trials as Topic | 13 | 2021 | 3719 | 0.730 |
Why?
|
| Antibodies, Monoclonal | 12 | 2020 | 4367 | 0.720 |
Why?
|
| Nephrectomy | 13 | 2013 | 779 | 0.710 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2022 | 15862 | 0.700 |
Why?
|
| Retrospective Studies | 98 | 2023 | 37905 | 0.700 |
Why?
|
| Genetic Predisposition to Disease | 29 | 2016 | 5539 | 0.690 |
Why?
|
| Polymorphism, Single Nucleotide | 31 | 2016 | 4549 | 0.690 |
Why?
|
| Robotic Surgical Procedures | 4 | 2021 | 481 | 0.690 |
Why?
|
| Endothelial Growth Factors | 12 | 2001 | 197 | 0.660 |
Why?
|
| DNA, Neoplasm | 12 | 2018 | 1910 | 0.660 |
Why?
|
| Lymphokines | 12 | 2001 | 272 | 0.650 |
Why?
|
| Survival Rate | 45 | 2021 | 12221 | 0.640 |
Why?
|
| Doxorubicin | 15 | 2020 | 3005 | 0.640 |
Why?
|
| Neoplasm Metastasis | 20 | 2019 | 5112 | 0.630 |
Why?
|
| Mycobacterium bovis | 3 | 2023 | 67 | 0.630 |
Why?
|
| Tumor Cells, Cultured | 25 | 2020 | 5395 | 0.610 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2019 | 973 | 0.600 |
Why?
|
| Urethral Neoplasms | 5 | 2009 | 60 | 0.600 |
Why?
|
| Interferons | 1 | 2018 | 291 | 0.600 |
Why?
|
| Epithelium | 2 | 2009 | 720 | 0.600 |
Why?
|
| Quinazolines | 5 | 2008 | 923 | 0.580 |
Why?
|
| Cadherins | 5 | 2009 | 660 | 0.570 |
Why?
|
| Receptors, Growth Factor | 4 | 2008 | 157 | 0.570 |
Why?
|
| Vascular Endothelial Growth Factors | 13 | 2007 | 212 | 0.570 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2017 | 607 | 0.560 |
Why?
|
| Patient Selection | 10 | 2021 | 2055 | 0.560 |
Why?
|
| Apoptosis | 26 | 2020 | 7591 | 0.560 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 622 | 0.550 |
Why?
|
| MicroRNAs | 10 | 2019 | 2947 | 0.550 |
Why?
|
| Vinblastine | 12 | 2020 | 453 | 0.550 |
Why?
|
| Immunohistochemistry | 31 | 2021 | 7548 | 0.540 |
Why?
|
| Mice, Inbred BALB C | 23 | 2006 | 2314 | 0.540 |
Why?
|
| Robotics | 5 | 2021 | 359 | 0.540 |
Why?
|
| Kaplan-Meier Estimate | 21 | 2021 | 6207 | 0.530 |
Why?
|
| Population Surveillance | 4 | 2011 | 627 | 0.530 |
Why?
|
| Salvage Therapy | 4 | 2020 | 2054 | 0.530 |
Why?
|
| Carcinoma, Small Cell | 6 | 2018 | 408 | 0.530 |
Why?
|
| Cell Differentiation | 4 | 2020 | 4078 | 0.530 |
Why?
|
| Neoplasm Grading | 13 | 2021 | 1742 | 0.520 |
Why?
|
| Risk Factors | 51 | 2021 | 17523 | 0.510 |
Why?
|
| Gene Expression Profiling | 19 | 2020 | 5159 | 0.510 |
Why?
|
| Cystoscopy | 5 | 2018 | 88 | 0.500 |
Why?
|
| RNA, Messenger | 21 | 2016 | 6150 | 0.490 |
Why?
|
| Keratin-18 | 1 | 2014 | 10 | 0.490 |
Why?
|
| Disease-Free Survival | 29 | 2021 | 10001 | 0.480 |
Why?
|
| Lymphatic Metastasis | 23 | 2020 | 4844 | 0.470 |
Why?
|
| Adult | 83 | 2021 | 77950 | 0.470 |
Why?
|
| Methotrexate | 12 | 2020 | 999 | 0.460 |
Why?
|
| Animals | 64 | 2020 | 59536 | 0.460 |
Why?
|
| Mice | 53 | 2020 | 34495 | 0.460 |
Why?
|
| Combined Modality Therapy | 30 | 2023 | 8865 | 0.450 |
Why?
|
| Immunotherapy | 7 | 2023 | 3341 | 0.450 |
Why?
|
| Treatment Failure | 6 | 2018 | 1391 | 0.440 |
Why?
|
| Prostatic Neoplasms | 15 | 2005 | 5767 | 0.430 |
Why?
|
| Cell Line, Tumor | 34 | 2017 | 14551 | 0.430 |
Why?
|
| Cell Division | 14 | 2013 | 2489 | 0.430 |
Why?
|
| Time Factors | 29 | 2021 | 12926 | 0.420 |
Why?
|
| RNA, Neoplasm | 3 | 2007 | 771 | 0.410 |
Why?
|
| Survival Analysis | 23 | 2018 | 9180 | 0.410 |
Why?
|
| Transcriptome | 4 | 2016 | 1859 | 0.400 |
Why?
|
| Polymorphism, Genetic | 9 | 2007 | 1450 | 0.400 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2017 | 726 | 0.390 |
Why?
|
| Vena Cava, Inferior | 3 | 2003 | 190 | 0.380 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2010 | 32 | 0.380 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 62 | 0.380 |
Why?
|
| Recombinant Proteins | 9 | 2017 | 2927 | 0.380 |
Why?
|
| Prostate | 6 | 2018 | 1088 | 0.370 |
Why?
|
| Genetic Variation | 9 | 2015 | 2086 | 0.360 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2007 | 1248 | 0.360 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 5 | 2014 | 62 | 0.360 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2014 | 5437 | 0.360 |
Why?
|
| Disease Models, Animal | 6 | 2017 | 7222 | 0.360 |
Why?
|
| Muscle, Smooth | 6 | 2020 | 236 | 0.360 |
Why?
|
| Genes, p53 | 4 | 2005 | 1090 | 0.350 |
Why?
|
| Mucous Membrane | 3 | 2020 | 271 | 0.350 |
Why?
|
| Urinary Diversion | 4 | 2020 | 69 | 0.340 |
Why?
|
| Mesoderm | 3 | 2010 | 404 | 0.340 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 1350 | 0.340 |
Why?
|
| Cell Transdifferentiation | 1 | 2009 | 112 | 0.340 |
Why?
|
| Biopsy, Needle | 3 | 2009 | 1363 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2016 | 4938 | 0.330 |
Why?
|
| Receptor, ErbB-3 | 2 | 2014 | 122 | 0.330 |
Why?
|
| Precision Medicine | 3 | 2016 | 1154 | 0.330 |
Why?
|
| Tumor Suppressor Protein p53 | 10 | 2016 | 3552 | 0.320 |
Why?
|
| Mitomycin | 3 | 2018 | 208 | 0.320 |
Why?
|
| Proportional Hazards Models | 19 | 2021 | 4988 | 0.310 |
Why?
|
| Multivariate Analysis | 16 | 2018 | 4298 | 0.310 |
Why?
|
| In Situ Hybridization | 8 | 2005 | 1037 | 0.310 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 7 | 2015 | 205 | 0.300 |
Why?
|
| Thrombosis | 3 | 2021 | 781 | 0.300 |
Why?
|
| Neoplasm Proteins | 7 | 2014 | 3230 | 0.300 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2021 | 551 | 0.290 |
Why?
|
| Paclitaxel | 4 | 2002 | 1996 | 0.290 |
Why?
|
| Case-Control Studies | 26 | 2016 | 6100 | 0.290 |
Why?
|
| Follow-Up Studies | 26 | 2021 | 14889 | 0.290 |
Why?
|
| Flow Cytometry | 2 | 2010 | 3033 | 0.290 |
Why?
|
| Muscles | 5 | 2023 | 416 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 13 | 2014 | 3639 | 0.290 |
Why?
|
| Genetic Loci | 3 | 2014 | 481 | 0.290 |
Why?
|
| Receptor, ErbB-2 | 3 | 2014 | 2518 | 0.290 |
Why?
|
| Telomere | 4 | 2014 | 505 | 0.280 |
Why?
|
| Peptide Fragments | 6 | 2014 | 1271 | 0.280 |
Why?
|
| Sirolimus | 2 | 2012 | 814 | 0.280 |
Why?
|
| Drugs, Investigational | 1 | 2007 | 135 | 0.280 |
Why?
|
| Predictive Value of Tests | 15 | 2019 | 4892 | 0.280 |
Why?
|
| Kidney Pelvis | 6 | 2021 | 102 | 0.280 |
Why?
|
| Cause of Death | 1 | 2009 | 752 | 0.270 |
Why?
|
| DNA Repair | 7 | 2011 | 1872 | 0.270 |
Why?
|
| Cohort Studies | 21 | 2021 | 9244 | 0.270 |
Why?
|
| Genome-Wide Association Study | 9 | 2016 | 2265 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2020 | 3821 | 0.260 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2007 | 661 | 0.260 |
Why?
|
| Blotting, Western | 11 | 2014 | 3536 | 0.260 |
Why?
|
| Carcinoma, Papillary | 3 | 2016 | 584 | 0.260 |
Why?
|
| Prospective Studies | 16 | 2021 | 12873 | 0.260 |
Why?
|
| Tissue Array Analysis | 6 | 2016 | 760 | 0.260 |
Why?
|
| Cetuximab | 6 | 2010 | 472 | 0.260 |
Why?
|
| Medical Oncology | 4 | 2014 | 1423 | 0.260 |
Why?
|
| Genotype | 20 | 2015 | 4109 | 0.260 |
Why?
|
| Drug Administration Schedule | 6 | 2016 | 3472 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2020 | 3251 | 0.250 |
Why?
|
| Hospitals | 2 | 2017 | 485 | 0.250 |
Why?
|
| Endothelium | 2 | 2002 | 158 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2004 | 272 | 0.250 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2016 | 1823 | 0.250 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2023 | 716 | 0.250 |
Why?
|
| Biomedical Research | 2 | 2018 | 806 | 0.250 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 669 | 0.250 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 650 | 0.240 |
Why?
|
| Diet | 4 | 2018 | 1440 | 0.240 |
Why?
|
| Boronic Acids | 5 | 2013 | 362 | 0.240 |
Why?
|
| Phosphatidylethanolamines | 2 | 1995 | 63 | 0.240 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 2 | 1995 | 58 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2012 | 2054 | 0.240 |
Why?
|
| Polyethyleneimine | 1 | 2003 | 18 | 0.230 |
Why?
|
| Cell Proliferation | 10 | 2020 | 7226 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2012 | 4757 | 0.230 |
Why?
|
| Adenocarcinoma | 9 | 2017 | 7789 | 0.230 |
Why?
|
| Cell Death | 4 | 2014 | 671 | 0.220 |
Why?
|
| Pyrazines | 5 | 2013 | 495 | 0.220 |
Why?
|
| Sensitivity and Specificity | 12 | 2020 | 4971 | 0.220 |
Why?
|
| Urinary Tract | 1 | 2023 | 82 | 0.220 |
Why?
|
| NF-kappa B | 3 | 2007 | 1549 | 0.220 |
Why?
|
| In Situ Nick-End Labeling | 6 | 2008 | 448 | 0.220 |
Why?
|
| Taxoids | 1 | 2006 | 967 | 0.220 |
Why?
|
| Risk Assessment | 14 | 2021 | 6869 | 0.220 |
Why?
|
| Thrombectomy | 1 | 2003 | 158 | 0.220 |
Why?
|
| Molecular Targeted Therapy | 5 | 2016 | 2330 | 0.210 |
Why?
|
| Oligopeptides | 4 | 1992 | 429 | 0.210 |
Why?
|
| Penile Neoplasms | 3 | 2013 | 161 | 0.210 |
Why?
|
| Geriatric Assessment | 3 | 2018 | 275 | 0.210 |
Why?
|
| Transplantation, Heterologous | 6 | 2010 | 1082 | 0.210 |
Why?
|
| Sex Counseling | 1 | 2021 | 16 | 0.200 |
Why?
|
| Leiomyosarcoma | 1 | 2003 | 223 | 0.200 |
Why?
|
| Diabetes Complications | 2 | 2020 | 305 | 0.200 |
Why?
|
| Down-Regulation | 7 | 2016 | 2074 | 0.200 |
Why?
|
| Risk | 10 | 2014 | 1972 | 0.200 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2000 | 18 | 0.200 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2014 | 272 | 0.200 |
Why?
|
| Smoking | 11 | 2011 | 2440 | 0.190 |
Why?
|
| Preoperative Care | 9 | 2017 | 1529 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 945 | 0.190 |
Why?
|
| Signal Transduction | 7 | 2017 | 11965 | 0.190 |
Why?
|
| Cluster Analysis | 4 | 2016 | 1053 | 0.190 |
Why?
|
| GATA3 Transcription Factor | 3 | 2020 | 146 | 0.190 |
Why?
|
| DNA Methylation | 4 | 2019 | 2669 | 0.190 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 669 | 0.190 |
Why?
|
| Organ Sparing Treatments | 2 | 2021 | 277 | 0.190 |
Why?
|
| Deoxycytidine | 7 | 2023 | 1353 | 0.190 |
Why?
|
| Leukocytes | 2 | 2014 | 422 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2011 | 181 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2020 | 2203 | 0.190 |
Why?
|
| Lymphocytes | 3 | 2019 | 1234 | 0.190 |
Why?
|
| Arylamine N-Acetyltransferase | 3 | 2010 | 41 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2012 | 2508 | 0.190 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2000 | 106 | 0.180 |
Why?
|
| Laparoscopy | 3 | 2016 | 1225 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2008 | 1489 | 0.180 |
Why?
|
| Urethra | 3 | 2018 | 144 | 0.180 |
Why?
|
| Microarray Analysis | 3 | 2021 | 392 | 0.180 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 306 | 0.180 |
Why?
|
| Ureter | 5 | 2021 | 209 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2010 | 1265 | 0.180 |
Why?
|
| Logistic Models | 8 | 2018 | 3441 | 0.180 |
Why?
|
| Transgenes | 1 | 2001 | 557 | 0.180 |
Why?
|
| Ultrasonography | 5 | 2018 | 1863 | 0.180 |
Why?
|
| Nutrition Assessment | 2 | 2018 | 169 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2001 | 852 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 2 | 2017 | 1130 | 0.170 |
Why?
|
| United States | 11 | 2021 | 15433 | 0.170 |
Why?
|
| Pelvic Exenteration | 1 | 1999 | 108 | 0.170 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 129 | 0.170 |
Why?
|
| Microcirculation | 4 | 2000 | 200 | 0.170 |
Why?
|
| Nomograms | 3 | 2020 | 313 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 332 | 0.170 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2007 | 256 | 0.170 |
Why?
|
| Antibodies | 1 | 2002 | 838 | 0.170 |
Why?
|
| Age Factors | 7 | 2021 | 5377 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2012 | 1678 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 7702 | 0.170 |
Why?
|
| Uroplakin II | 2 | 2016 | 15 | 0.160 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 149 | 0.160 |
Why?
|
| Texas | 11 | 2018 | 6311 | 0.160 |
Why?
|
| Whole Genome Sequencing | 2 | 2017 | 338 | 0.160 |
Why?
|
| Drug Synergism | 5 | 2007 | 1313 | 0.160 |
Why?
|
| Urologic Surgical Procedures | 2 | 2017 | 93 | 0.160 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 1656 | 0.160 |
Why?
|
| Cell Cycle | 4 | 2008 | 2084 | 0.160 |
Why?
|
| Sarcoma | 3 | 2019 | 1725 | 0.150 |
Why?
|
| Transfection | 6 | 2010 | 2944 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2016 | 141 | 0.150 |
Why?
|
| Aurora Kinase A | 2 | 2017 | 202 | 0.150 |
Why?
|
| Caspases | 5 | 2014 | 661 | 0.150 |
Why?
|
| Comet Assay | 3 | 2007 | 59 | 0.150 |
Why?
|
| Pharmaceutical Solutions | 1 | 2017 | 22 | 0.150 |
Why?
|
| Membrane Glycoproteins | 3 | 2009 | 1073 | 0.150 |
Why?
|
| Clinical Protocols | 3 | 2011 | 467 | 0.150 |
Why?
|
| Phthalimides | 1 | 1997 | 5 | 0.150 |
Why?
|
| Urination Disorders | 1 | 2017 | 61 | 0.150 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 43 | 0.150 |
Why?
|
| Snail Family Transcription Factors | 1 | 2017 | 120 | 0.150 |
Why?
|
| Liposomes | 5 | 1995 | 684 | 0.150 |
Why?
|
| Glutathione Transferase | 2 | 2009 | 359 | 0.150 |
Why?
|
| Clonal Evolution | 1 | 2019 | 253 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2017 | 1555 | 0.150 |
Why?
|
| Sex Factors | 3 | 2021 | 2139 | 0.150 |
Why?
|
| Blotting, Northern | 3 | 2003 | 682 | 0.150 |
Why?
|
| Neoplasms | 6 | 2018 | 15193 | 0.140 |
Why?
|
| Excipients | 1 | 2016 | 17 | 0.140 |
Why?
|
| Lymph Nodes | 4 | 2015 | 2967 | 0.140 |
Why?
|
| Biomarkers | 5 | 2018 | 5047 | 0.140 |
Why?
|
| Nuclear Proteins | 4 | 2019 | 3343 | 0.140 |
Why?
|
| Thiazolidinediones | 1 | 2017 | 148 | 0.140 |
Why?
|
| Collagenases | 3 | 2001 | 74 | 0.140 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2016 | 33 | 0.140 |
Why?
|
| Prostatectomy | 7 | 2006 | 962 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 115 | 0.140 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2007 | 355 | 0.140 |
Why?
|
| Gene Transfer Techniques | 4 | 2003 | 716 | 0.140 |
Why?
|
| Matrix Metalloproteinases | 2 | 2007 | 143 | 0.140 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 202 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2016 | 39 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 748 | 0.140 |
Why?
|
| Luminescence | 3 | 2010 | 44 | 0.140 |
Why?
|
| Vaginal Neoplasms | 1 | 1997 | 152 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 134 | 0.140 |
Why?
|
| DNA | 2 | 2006 | 2693 | 0.140 |
Why?
|
| Transcription Factors | 5 | 2016 | 5270 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 64 | 0.140 |
Why?
|
| Inguinal Canal | 2 | 2013 | 60 | 0.140 |
Why?
|
| Postoperative Complications | 7 | 2018 | 5542 | 0.140 |
Why?
|
| Accidental Falls | 1 | 2017 | 142 | 0.130 |
Why?
|
| Phosphorylation | 7 | 2014 | 4804 | 0.130 |
Why?
|
| Feasibility Studies | 4 | 2012 | 2292 | 0.130 |
Why?
|
| Phenotype | 4 | 2020 | 6295 | 0.130 |
Why?
|
| Folic Acid | 1 | 2018 | 349 | 0.130 |
Why?
|
| Biopsy | 6 | 2020 | 3443 | 0.130 |
Why?
|
| Propensity Score | 1 | 2018 | 750 | 0.130 |
Why?
|
| Uroplakin III | 1 | 2014 | 8 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 7 | 2009 | 3101 | 0.130 |
Why?
|
| Neutrophils | 1 | 2019 | 835 | 0.130 |
Why?
|
| Fractures, Bone | 1 | 2017 | 291 | 0.130 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 475 | 0.130 |
Why?
|
| Young Adult | 9 | 2017 | 21445 | 0.130 |
Why?
|
| Linkage Disequilibrium | 5 | 2016 | 460 | 0.130 |
Why?
|
| Hypoxia | 2 | 2010 | 443 | 0.120 |
Why?
|
| Gene Expression | 6 | 2009 | 3570 | 0.120 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2007 | 57 | 0.120 |
Why?
|
| Malnutrition | 1 | 2017 | 218 | 0.120 |
Why?
|
| Postoperative Care | 4 | 2012 | 739 | 0.120 |
Why?
|
| Heterografts | 1 | 2017 | 733 | 0.120 |
Why?
|
| Ki-67 Antigen | 1 | 2016 | 666 | 0.120 |
Why?
|
| Haplotypes | 6 | 2013 | 856 | 0.120 |
Why?
|
| Genital Neoplasms, Female | 1 | 2021 | 735 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2015 | 1538 | 0.120 |
Why?
|
| Luciferases | 4 | 2012 | 445 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 1879 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 211 | 0.120 |
Why?
|
| Casein Kinase II | 1 | 2014 | 69 | 0.120 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2013 | 17 | 0.120 |
Why?
|
| International Agencies | 2 | 2011 | 107 | 0.120 |
Why?
|
| Gene Frequency | 7 | 2014 | 1163 | 0.120 |
Why?
|
| DNA Contamination | 1 | 2013 | 3 | 0.120 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 254 | 0.110 |
Why?
|
| Transcription, Genetic | 5 | 2019 | 3154 | 0.110 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 3 | 2008 | 96 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 311 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 690 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2012 | 1546 | 0.110 |
Why?
|
| Drinking | 1 | 2013 | 54 | 0.110 |
Why?
|
| Odds Ratio | 6 | 2017 | 2316 | 0.110 |
Why?
|
| Diagnosis, Differential | 4 | 2014 | 4744 | 0.110 |
Why?
|
| Video-Assisted Surgery | 1 | 2013 | 28 | 0.110 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 374 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 586 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 336 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 259 | 0.110 |
Why?
|
| Telomerase | 2 | 2014 | 525 | 0.110 |
Why?
|
| Glutathione | 1 | 2015 | 368 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2014 | 665 | 0.110 |
Why?
|
| SEER Program | 3 | 2016 | 1000 | 0.110 |
Why?
|
| Dysuria | 1 | 2012 | 7 | 0.110 |
Why?
|
| Genomics | 2 | 2020 | 2738 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1249 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 104 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 2 | 2009 | 585 | 0.110 |
Why?
|
| Laminin | 3 | 2003 | 194 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1026 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 430 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1819 | 0.110 |
Why?
|
| Penis | 1 | 2013 | 123 | 0.110 |
Why?
|
| HeLa Cells | 2 | 2013 | 1643 | 0.110 |
Why?
|
| Cell Cycle Proteins | 3 | 2008 | 2045 | 0.110 |
Why?
|
| Hematuria | 2 | 2007 | 85 | 0.110 |
Why?
|
| Inflammation | 3 | 2008 | 2522 | 0.100 |
Why?
|
| Contraindications | 1 | 2012 | 150 | 0.100 |
Why?
|
| Macrophage Activation | 4 | 1995 | 148 | 0.100 |
Why?
|
| Mutation | 9 | 2019 | 15179 | 0.100 |
Why?
|
| Proteoglycans | 3 | 2003 | 259 | 0.100 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 1054 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 2359 | 0.100 |
Why?
|
| PPAR gamma | 4 | 2016 | 229 | 0.100 |
Why?
|
| Amines | 1 | 2012 | 85 | 0.100 |
Why?
|
| Microscopy, Confocal | 3 | 2011 | 663 | 0.100 |
Why?
|
| Drug Therapy | 2 | 2015 | 205 | 0.100 |
Why?
|
| Nephroureterectomy | 2 | 2022 | 39 | 0.100 |
Why?
|
| Telomere Homeostasis | 1 | 2012 | 73 | 0.100 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 565 | 0.100 |
Why?
|
| Caspases, Initiator | 1 | 2011 | 16 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2013 | 182 | 0.100 |
Why?
|
| Meat | 1 | 2012 | 87 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 1290 | 0.100 |
Why?
|
| Interleukin-2 | 2 | 1992 | 842 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 119 | 0.100 |
Why?
|
| Thrombospondin 1 | 2 | 2002 | 55 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 1999 | 1202 | 0.100 |
Why?
|
| Models, Biological | 2 | 2011 | 3254 | 0.100 |
Why?
|
| Preoperative Period | 3 | 2021 | 344 | 0.100 |
Why?
|
| beta Catenin | 1 | 2015 | 688 | 0.100 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 1162 | 0.100 |
Why?
|
| Fatigue | 1 | 2017 | 1239 | 0.100 |
Why?
|
| Chromosome Mapping | 3 | 2010 | 1471 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2003 | 621 | 0.100 |
Why?
|
| Recurrence | 5 | 2014 | 4758 | 0.100 |
Why?
|
| Interferon-gamma | 2 | 1992 | 1144 | 0.100 |
Why?
|
| Gene Silencing | 2 | 2018 | 837 | 0.100 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 79 | 0.100 |
Why?
|
| Blood Vessels | 2 | 2002 | 217 | 0.100 |
Why?
|
| Models, Economic | 2 | 2008 | 101 | 0.090 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2010 | 39 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 447 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2010 | 169 | 0.090 |
Why?
|
| Up-Regulation | 4 | 2008 | 2450 | 0.090 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2009 | 22 | 0.090 |
Why?
|
| Reference Values | 5 | 2015 | 1099 | 0.090 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2010 | 41 | 0.090 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 2007 | 104 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 153 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2010 | 172 | 0.090 |
Why?
|
| Pyrimidinones | 1 | 2012 | 314 | 0.090 |
Why?
|
| Cetrimonium Compounds | 1 | 2009 | 6 | 0.090 |
Why?
|
| Perioperative Period | 2 | 2021 | 155 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2015 | 1217 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2019 | 1987 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 244 | 0.090 |
Why?
|
| Surface-Active Agents | 1 | 2009 | 41 | 0.090 |
Why?
|
| Nanotechnology | 1 | 2010 | 137 | 0.090 |
Why?
|
| Nanotubes | 1 | 2009 | 28 | 0.090 |
Why?
|
| Immunochemistry | 3 | 2011 | 61 | 0.090 |
Why?
|
| Obesity | 2 | 2020 | 2884 | 0.090 |
Why?
|
| Retinoblastoma Protein | 3 | 2008 | 335 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 272 | 0.090 |
Why?
|
| DNA Mutational Analysis | 3 | 2008 | 2283 | 0.090 |
Why?
|
| Collagen | 3 | 2003 | 752 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2012 | 369 | 0.090 |
Why?
|
| Polyethylene Glycols | 2 | 2010 | 615 | 0.090 |
Why?
|
| DNA Damage | 3 | 2007 | 1954 | 0.090 |
Why?
|
| Databases, Genetic | 3 | 2020 | 745 | 0.080 |
Why?
|
| Necrosis | 1 | 2010 | 580 | 0.080 |
Why?
|
| Endothelium, Vascular | 3 | 2005 | 891 | 0.080 |
Why?
|
| Cell Dedifferentiation | 1 | 2009 | 96 | 0.080 |
Why?
|
| Vagina | 2 | 2021 | 317 | 0.080 |
Why?
|
| Bevacizumab | 2 | 2015 | 938 | 0.080 |
Why?
|
| Photochemotherapy | 1 | 2009 | 96 | 0.080 |
Why?
|
| Office Visits | 1 | 2009 | 97 | 0.080 |
Why?
|
| Pelvis | 4 | 2016 | 362 | 0.080 |
Why?
|
| Bortezomib | 5 | 2013 | 543 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2005 | 528 | 0.080 |
Why?
|
| Pleural Effusion | 1 | 1990 | 201 | 0.080 |
Why?
|
| Genes, cdc | 1 | 2008 | 81 | 0.080 |
Why?
|
| Genes | 3 | 2007 | 491 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 78 | 0.080 |
Why?
|
| Receptor, ErbB-4 | 1 | 2007 | 23 | 0.080 |
Why?
|
| Ureteroscopy | 2 | 2018 | 46 | 0.080 |
Why?
|
| Androgens | 2 | 2002 | 511 | 0.080 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 424 | 0.080 |
Why?
|
| Quality of Life | 2 | 2020 | 4532 | 0.080 |
Why?
|
| Vitamin A | 1 | 2008 | 94 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 321 | 0.080 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 260 | 0.080 |
Why?
|
| Fenretinide | 1 | 2008 | 96 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2010 | 652 | 0.080 |
Why?
|
| Gold | 1 | 2009 | 270 | 0.080 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2018 | 55 | 0.080 |
Why?
|
| Mutagens | 1 | 2008 | 187 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 290 | 0.080 |
Why?
|
| Administration, Topical | 2 | 2018 | 257 | 0.080 |
Why?
|
| Fruit | 1 | 2009 | 294 | 0.080 |
Why?
|
| Lung Neoplasms | 7 | 2017 | 11538 | 0.070 |
Why?
|
| Transcription Factor AP-2 | 1 | 2007 | 79 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 1756 | 0.070 |
Why?
|
| Isothiocyanates | 1 | 2007 | 44 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2007 | 47 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 6009 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2008 | 369 | 0.070 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2007 | 53 | 0.070 |
Why?
|
| Vitamin K 3 | 1 | 2006 | 6 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2003 | 4557 | 0.070 |
Why?
|
| Hair Dyes | 1 | 2006 | 4 | 0.070 |
Why?
|
| Regional Medical Programs | 1 | 2006 | 19 | 0.070 |
Why?
|
| Vegetables | 1 | 2009 | 325 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 3 | 2010 | 769 | 0.070 |
Why?
|
| Chylous Ascites | 1 | 2006 | 25 | 0.070 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 119 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2007 | 4821 | 0.070 |
Why?
|
| Benzamides | 1 | 2012 | 1832 | 0.070 |
Why?
|
| DNA Fragmentation | 2 | 2004 | 198 | 0.070 |
Why?
|
| Clinical Chemistry Tests | 1 | 2006 | 12 | 0.070 |
Why?
|
| Europe | 3 | 2014 | 649 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2006 | 566 | 0.070 |
Why?
|
| DNA Primers | 3 | 2013 | 1399 | 0.070 |
Why?
|
| Carboprost | 1 | 1995 | 4 | 0.070 |
Why?
|
| Carcinosarcoma | 1 | 2007 | 146 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 1 | 2007 | 246 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1997 | 1833 | 0.070 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 2009 | 31 | 0.070 |
Why?
|
| Ascorbic Acid | 1 | 2006 | 131 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1165 | 0.070 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2006 | 70 | 0.070 |
Why?
|
| Pathology, Clinical | 1 | 2007 | 152 | 0.070 |
Why?
|
| Autophagy | 1 | 2012 | 927 | 0.070 |
Why?
|
| Cytokines | 1 | 2015 | 2809 | 0.070 |
Why?
|
| Nylons | 2 | 2004 | 19 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2012 | 1129 | 0.070 |
Why?
|
| Urine | 2 | 2006 | 143 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2010 | 554 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 821 | 0.070 |
Why?
|
| Vitamins | 1 | 2006 | 157 | 0.070 |
Why?
|
| Consensus | 2 | 2020 | 978 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2008 | 2307 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 1303 | 0.070 |
Why?
|
| Gels | 1 | 2005 | 105 | 0.070 |
Why?
|
| Incidence | 6 | 2018 | 5673 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2009 | 874 | 0.070 |
Why?
|
| Family Health | 1 | 2006 | 325 | 0.070 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2004 | 6 | 0.070 |
Why?
|
| Cyclins | 2 | 2004 | 456 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 375 | 0.060 |
Why?
|
| Proteomics | 1 | 2012 | 1380 | 0.060 |
Why?
|
| Drug Carriers | 4 | 1995 | 327 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2003 | 542 | 0.060 |
Why?
|
| Tissue Banks | 1 | 2005 | 55 | 0.060 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 332 | 0.060 |
Why?
|
| Cell Movement | 3 | 2017 | 2466 | 0.060 |
Why?
|
| Radiotherapy | 2 | 2014 | 1824 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 2216 | 0.060 |
Why?
|
| Genes, erbB | 1 | 2004 | 26 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2005 | 118 | 0.060 |
Why?
|
| Cystitis | 1 | 1995 | 107 | 0.060 |
Why?
|
| Wound Healing | 1 | 2009 | 815 | 0.060 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 1070 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 4314 | 0.060 |
Why?
|
| Disease Management | 1 | 2009 | 1052 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2010 | 992 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2005 | 260 | 0.060 |
Why?
|
| Caspase Inhibitors | 3 | 2011 | 95 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 2009 | 1506 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1362 | 0.060 |
Why?
|
| Multigene Family | 1 | 2005 | 425 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2819 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 136 | 0.060 |
Why?
|
| Interferon Type I | 1 | 2004 | 250 | 0.060 |
Why?
|
| Point Mutation | 1 | 2006 | 769 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2009 | 1498 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2004 | 176 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2009 | 732 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2006 | 498 | 0.060 |
Why?
|
| Alleles | 4 | 2014 | 2437 | 0.060 |
Why?
|
| Caspase 8 | 3 | 2011 | 145 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 213 | 0.060 |
Why?
|
| Genes, Reporter | 2 | 2009 | 798 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 170 | 0.060 |
Why?
|
| RNA Interference | 3 | 2013 | 1408 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2576 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2008 | 674 | 0.050 |
Why?
|
| Testicular Neoplasms | 1 | 2006 | 529 | 0.050 |
Why?
|
| Equipment Design | 1 | 2006 | 1204 | 0.050 |
Why?
|
| North America | 2 | 2014 | 314 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 109 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 585 | 0.050 |
Why?
|
| Protein Binding | 2 | 2012 | 3438 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 475 | 0.050 |
Why?
|
| Epistasis, Genetic | 2 | 2012 | 119 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2017 | 665 | 0.050 |
Why?
|
| Dyspareunia | 1 | 2021 | 11 | 0.050 |
Why?
|
| Fibrin | 1 | 2021 | 82 | 0.050 |
Why?
|
| Sexual Health | 1 | 2021 | 15 | 0.050 |
Why?
|
| Algorithms | 3 | 2008 | 3890 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 1323 | 0.050 |
Why?
|
| Urinary Catheterization | 2 | 2018 | 117 | 0.050 |
Why?
|
| Colorimetry | 1 | 2001 | 31 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 287 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 1960 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 1064 | 0.050 |
Why?
|
| Research Design | 2 | 2021 | 1544 | 0.050 |
Why?
|
| Hemorrhage | 1 | 1995 | 712 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2003 | 1620 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2003 | 262 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2000 | 182 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2012 | 621 | 0.050 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2021 | 70 | 0.050 |
Why?
|
| Tyrosine | 1 | 2002 | 498 | 0.050 |
Why?
|
| Keratin-6 | 1 | 2020 | 39 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2013 | 842 | 0.050 |
Why?
|
| Keratin-5 | 1 | 2020 | 57 | 0.050 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 118 | 0.050 |
Why?
|
| Warfarin | 1 | 2021 | 152 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2002 | 423 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 5687 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 1995 | 1581 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2000 | 289 | 0.050 |
Why?
|
| RNA, Antisense | 1 | 2000 | 69 | 0.050 |
Why?
|
| Ifosfamide | 2 | 2012 | 344 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 7551 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 3 | 2008 | 694 | 0.050 |
Why?
|
| Growth Substances | 1 | 2001 | 300 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 126 | 0.050 |
Why?
|
| Image Cytometry | 2 | 1997 | 47 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2021 | 233 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2001 | 177 | 0.040 |
Why?
|
| RNA Stability | 1 | 2000 | 125 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2005 | 1274 | 0.040 |
Why?
|
| International Cooperation | 1 | 2021 | 323 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2019 | 92 | 0.040 |
Why?
|
| Carboplatin | 1 | 2022 | 823 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 1258 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5637 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2001 | 429 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 403 | 0.040 |
Why?
|
| Killer Cells, Natural | 3 | 1999 | 904 | 0.040 |
Why?
|
| Organ Size | 1 | 2000 | 690 | 0.040 |
Why?
|
| Epigenesis, Genetic | 2 | 2018 | 1399 | 0.040 |
Why?
|
| Computational Biology | 2 | 2016 | 1271 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 602 | 0.040 |
Why?
|
| DNA Helicases | 2 | 2016 | 434 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2001 | 345 | 0.040 |
Why?
|
| Patient Preference | 1 | 2021 | 218 | 0.040 |
Why?
|
| Cryotherapy | 1 | 1999 | 67 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 310 | 0.040 |
Why?
|
| Interferon-beta | 1 | 1999 | 102 | 0.040 |
Why?
|
| Capillaries | 1 | 1998 | 99 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 175 | 0.040 |
Why?
|
| Arthritis, Gouty | 1 | 2018 | 7 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2007 | 3203 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 61 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 455 | 0.040 |
Why?
|
| Taiwan | 1 | 2018 | 93 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 285 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2013 | 886 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2001 | 507 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2010 | 756 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1997 | 136 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 483 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 217 | 0.040 |
Why?
|
| Epithelial Cells | 3 | 2010 | 1818 | 0.040 |
Why?
|
| Drug Stability | 1 | 2017 | 105 | 0.040 |
Why?
|
| Enzyme Activation | 3 | 2005 | 1764 | 0.040 |
Why?
|
| Endoscopy | 2 | 2011 | 479 | 0.040 |
Why?
|
| Caspase 3 | 2 | 2011 | 471 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2021 | 611 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 1586 | 0.040 |
Why?
|
| Solubility | 1 | 2017 | 242 | 0.040 |
Why?
|
| Cell Line | 3 | 2010 | 5114 | 0.040 |
Why?
|
| Exercise | 2 | 2018 | 1183 | 0.040 |
Why?
|
| Keratin-14 | 1 | 2016 | 24 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 657 | 0.040 |
Why?
|
| Aging | 1 | 2005 | 1582 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 678 | 0.030 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2016 | 85 | 0.030 |
Why?
|
| Base Sequence | 2 | 2013 | 4917 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 309 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 787 | 0.030 |
Why?
|
| Microsatellite Repeats | 2 | 2008 | 575 | 0.030 |
Why?
|
| Cell Growth Processes | 2 | 2006 | 342 | 0.030 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 1996 | 82 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 292 | 0.030 |
Why?
|
| Liquid Biopsy | 1 | 2016 | 158 | 0.030 |
Why?
|
| Glutathione Synthase | 1 | 2015 | 6 | 0.030 |
Why?
|
| Molecular Epidemiology | 2 | 2007 | 246 | 0.030 |
Why?
|
| Cryosurgery | 1 | 1997 | 167 | 0.030 |
Why?
|
| Urogenital Neoplasms | 1 | 1996 | 108 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2015 | 61 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 1995 | 85 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 1995 | 66 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 829 | 0.030 |
Why?
|
| Gene Amplification | 2 | 2008 | 731 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 249 | 0.030 |
Why?
|
| Retroperitoneal Space | 2 | 2006 | 145 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 677 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2006 | 339 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1997 | 571 | 0.030 |
Why?
|
| Gamma Rays | 2 | 2007 | 242 | 0.030 |
Why?
|
| Length of Stay | 2 | 2018 | 1900 | 0.030 |
Why?
|
| Life Style | 1 | 2018 | 612 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 697 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 1996 | 435 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2005 | 157 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 548 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2001 | 1648 | 0.030 |
Why?
|
| Karyotyping | 1 | 1995 | 1022 | 0.030 |
Why?
|
| Religion | 1 | 2014 | 91 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1225 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 1996 | 2231 | 0.030 |
Why?
|
| India | 1 | 2014 | 301 | 0.030 |
Why?
|
| Cell Separation | 1 | 1995 | 612 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 558 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1996 | 577 | 0.030 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2012 | 42 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2012 | 30 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 627 | 0.030 |
Why?
|
| alpha-Defensins | 1 | 2012 | 16 | 0.030 |
Why?
|
| Interleukins | 1 | 2015 | 325 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1997 | 1544 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 854 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 276 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 799 | 0.030 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2012 | 66 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1992 | 93 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2012 | 159 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2018 | 717 | 0.030 |
Why?
|
| Kidney | 1 | 2021 | 2146 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2012 | 93 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 4849 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 2488 | 0.030 |
Why?
|
| Patient Compliance | 1 | 1996 | 667 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 1991 | 67 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2012 | 629 | 0.030 |
Why?
|
| Cooking | 1 | 2012 | 66 | 0.030 |
Why?
|
| Adolescent | 1 | 2012 | 31252 | 0.030 |
Why?
|
| Demography | 1 | 2012 | 435 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 1084 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2010 | 14 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2011 | 82 | 0.020 |
Why?
|
| Exons | 2 | 2006 | 1328 | 0.020 |
Why?
|
| Manganese Compounds | 1 | 2010 | 14 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1516 | 0.020 |
Why?
|
| Urography | 1 | 2010 | 43 | 0.020 |
Why?
|
| Genetic Phenomena | 1 | 2010 | 5 | 0.020 |
Why?
|
| Spain | 1 | 2010 | 113 | 0.020 |
Why?
|
| Urinalysis | 1 | 2011 | 84 | 0.020 |
Why?
|
| Coculture Techniques | 2 | 2005 | 626 | 0.020 |
Why?
|
| Registries | 2 | 2009 | 2170 | 0.020 |
Why?
|
| Macrophages | 2 | 1999 | 1304 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 691 | 0.020 |
Why?
|
| Dimerization | 1 | 2010 | 304 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 2483 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 1869 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 521 | 0.020 |
Why?
|
| Magnetics | 1 | 2010 | 107 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2011 | 166 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 1077 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 195 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2010 | 140 | 0.020 |
Why?
|
| Swine | 2 | 2005 | 1541 | 0.020 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2011 | 204 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Models, Statistical | 2 | 2007 | 1171 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 787 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2009 | 223 | 0.020 |
Why?
|
| gamma-Tocopherol | 1 | 2008 | 7 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2008 | 189 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 317 | 0.020 |
Why?
|
| Laser Scanning Cytometry | 1 | 2007 | 16 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2010 | 417 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2022 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 810 | 0.020 |
Why?
|
| Lipids | 1 | 1991 | 644 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2013 | 1335 | 0.020 |
Why?
|
| Energy Intake | 1 | 2010 | 515 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 717 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 1143 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 870 | 0.020 |
Why?
|
| Diploidy | 1 | 2007 | 114 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2007 | 209 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 437 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 1546 | 0.020 |
Why?
|
| Family | 1 | 2010 | 736 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 2086 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 495 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2007 | 156 | 0.020 |
Why?
|
| Heterozygote | 1 | 2009 | 1020 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 3 | 1997 | 993 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 785 | 0.020 |
Why?
|
| S Phase | 1 | 2007 | 281 | 0.020 |
Why?
|
| G1 Phase | 1 | 2007 | 285 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 698 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 866 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2006 | 173 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 1995 | 159 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 483 | 0.020 |
Why?
|
| Biotin | 1 | 2005 | 69 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 1 | 2005 | 25 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2005 | 249 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2005 | 163 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 6089 | 0.020 |
Why?
|
| Counseling | 1 | 2008 | 381 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2005 | 46 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 161 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1046 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 1664 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2005 | 109 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 644 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 371 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 2195 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 931 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 1183 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 3569 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2009 | 1152 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2004 | 334 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 598 | 0.010 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2004 | 129 | 0.010 |
Why?
|
| DNA Repair Enzymes | 1 | 2005 | 237 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1999 | 675 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2006 | 974 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 869 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2005 | 576 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2006 | 875 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2004 | 553 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 239 | 0.010 |
Why?
|
| Rats | 1 | 1992 | 6086 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 882 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 639 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 587 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 4053 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 251 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2004 | 249 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 694 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 376 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 1033 | 0.010 |
Why?
|
| CD36 Antigens | 1 | 2002 | 53 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 2002 | 72 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2008 | 808 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1443 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 195 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 848 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 750 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 589 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2005 | 1038 | 0.010 |
Why?
|
| Ileum | 1 | 2001 | 165 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 1013 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2006 | 1299 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1996 | 4638 | 0.010 |
Why?
|
| Global Health | 1 | 2005 | 657 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2002 | 368 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 4320 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5061 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2000 | 149 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5319 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1991 | 3869 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1999 | 573 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1999 | 875 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 418 | 0.010 |
Why?
|
| Ploidies | 1 | 1997 | 248 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 4143 | 0.010 |
Why?
|
| Laparotomy | 1 | 1997 | 211 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1996 | 222 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1996 | 114 | 0.010 |
Why?
|
| Adenoviridae Infections | 1 | 1996 | 125 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1999 | 1869 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1997 | 422 | 0.010 |
Why?
|
| Palpation | 1 | 1993 | 49 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1994 | 445 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1995 | 477 | 0.010 |
Why?
|
| Microbial Collagenase | 1 | 1992 | 17 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1996 | 747 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1999 | 2803 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 1997 | 631 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1996 | 1385 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 6942 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1997 | 1682 | 0.010 |
Why?
|
| Cell Communication | 1 | 1991 | 509 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1996 | 8223 | 0.000 |
Why?
|